8 Results for "

NOG mice

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "NOG mice" in MCE Product Catalog:

Cat. No.: HY-164899
CAS No.: 2765091-45-8
Synonyms: 2-aminopyridine-3-carboxylic acid imidazolide
Target:  

DNA/RNA Synthesis

Research Areas:  

Infection

2A3 (2-aminopyridine-3-carboxylic acid imidazolide) is a covalent probe reagent for Selective 2'-Hydroxyl Acylation analyzed by Primer Extension (SHAPE) that targets the RNA ribose 2'-OH group. 2A3 efficiently permeates the biological membranes of Gram-negative bacteria, Gram-positive bacteria, and mammalian cells. 2A3 exhibits no base bias and specifically labels conformationally flexible, unpaired regions within RNA. 2A3 forms covalent adducts by acylating the 2'-OH groups of flexible RNA residues. When combined with SHAPE-MaP (mutational profiling) sequencing technology, these modification sites are converted into detectable mutational signals, thereby accurately reflecting local RNA backbone flexibility and base-pairing status. 2A3 is primarily utilized in molecular biology and transcriptomics research, including the resolution of RNA structuromes in living cells, the study of RNA folding regulatory mechanisms, and the investigation of non-coding RNA functions .
loading...
    loading...
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI-315; BH2950

Target:  

EGFR PD-1/PD-L1

Research Areas:  

Cancer

Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .
loading...
    loading...
Cat. No.: HY-P99836
CAS No.: 2244739-29-3
Synonyms: IBI101
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
loading...
    loading...
Cat. No.: HY-163532
CAS No.: 2309398-79-4
Target:  

Sirtuin

Research Areas:  

Infection

FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC50 of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication .
loading...
    loading...
Cat. No.: HY-P991587

Target:  

Orphan GPCR

Research Areas:  

Cancer

SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
loading...
    loading...
Cat. No.: HY-P992381

Target:  

Drug Derivative

Research Areas:  

Cancer

IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
loading...
    loading...
Cat. No.: HY-184500
CAS No.: 2923223-81-6
Research Areas:  

Cancer

TNG917 is a potent, selective EHMT1/2 inhibitor with oral activity. TNG917 reduces H3K9me2-mediated transcriptional repression, restores interferon-stimulated gene expression, promotes the secretion of T-cell chemokines such as CXCL10, and converts immunologically cold tumors into T-cell inflamed tumors. TNG917 is applicable to studies on immunologically cold tumors, colorectal cancer, anti-tumor immunity, interferon signaling pathways and epigenetic immune escape .
loading...
    loading...
Cat. No.: HY-187562
Target:  

Wee1 CDK

Research Areas:  

Cancer

PKMYT1-IN-15 is an orally active PKMYT1 inhibitor with an IC50 of 6.02 nM. PKMYT1-IN-15 inhibits the phosphorylation of CDK1 at Thr14. As an antiproliferative agent, DNA damage inducer and antitumor agent, PKMYT1-IN-15 triggers replication-associated DNA damage and cell death in CCNE1-amplified cancer cells, and suppresses tumor growth in the OVCAR3 xenograft model. PKMYT1-IN-15 can be used for the research of CCNE1-amplified cancers (e.g., ovarian cancer, breast cancer) .
loading...
    loading...